LRIG1 is a prognostic biomarker in non-small cell lung cancer

Kvarnbrink, Samuel; Karlsson, Terese; Edlund, Karolina; Botling, Johan; Lindquist, David; Jirström, Karin; Micke, Patrick; Henriksson, Roger; Johansson, Mikael; Hedman, Håkan

doi:10.3109/0284186x.2015.1021427

Cited by 27 publications

(27 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The most common histological type of PVC is squamous cell carcinoma, which made up the majority of our samples. In agreement with our results, previous studies on squamous cell carcinomas of the cervix and oropharynx, breast [ 24 ], skin [ 34 ], and non-small cell lung cancer [ 22 , 23 ] showed that high LRIG1 expression is associated with improved prognosis. In a study of squamous cell carcinoma of the skin, LRIG1 showed the highest expression in well-differentiated tumours, and these patients also proved to have the best survival [ 34 ].…”

Section: Discussionsupporting

confidence: 93%

“…LRIG1 has been proposed to function as a tumour suppressor through negative regulation of oncogenic receptor tyrosine kinases, such as members of the ERBB family, MET and RET receptors, and PDGFRA [ 19 ]. LRIG1 expression is of prognostic significance and is associated with good prognosis in various human cancers, including cervical cancer [ 20 , 21 ], non-small-cell lung cancer [ 22 , 23 ], breast cancer [ 24 ], and others [ 18 ]. In cervical cancer, the variation in the number of LRIG1 gene copies and promoter methylation patterns are associated with patient survival [ 25 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Expression of LRIG proteins as possible prognostic factors in primary vaginal carcinoma

et al. 2017

Self Cite

View full text Add to dashboard Cite

BackgroundPrimary vaginal carcinoma (PVC) is a rare malignancy. Established prognostic factors include tumour stage and age at diagnosis. The leucine-rich repeats and immunoglobuline-like domains (LRIG)-1 protein functions as a tumour suppressor, but less is known about the functions of LRIG2 and LRIG3. The present study aimed to evaluate the expression of LRIG proteins and analyse their possible associations with clinical characteristics and survival in a cohort of PVC patients.MethodsWe used immunohistochemistry to investigate LRIG1, LRIG2, and LRIG3 expression in tumour samples from a consecutive cohort of 70 PVC patients. The association between LRIG protein expression and clinical characteristics and cancer-specific survival was investigated using univariate and multivariate analyses.ResultsThe majority of PVC patients (72%) had >50% LRIG1- and LRIG2-positive cells, and no or low LRIG3-positive cells. HPV status was significantly correlated with LRIG1 expression (p = 0.0047). Having high LRIG1 expression was significantly correlated with superior cancer-specific survival in univariate and multivariate analyses. LRIG2 and LRIG3 expression did not significantly correlate with clinical characteristics or survival.ConclusionLRIG1 expression might be of interest as a prognostic marker in PVC patients, whereas the role of LRIG2 and LRIG3 expression remains to be clarified.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Introductionmentioning

confidence: 99%

Expression of LRIG proteins as possible prognostic factors in primary vaginal carcinoma

et al. 2017

Self Cite

View full text Add to dashboard Cite

show abstract

“…In a meta-analysis of gene expression and patient outcome in ovarian serous carcinoma, Lrig1 was identified as one single gene prognostic biomarker that predicted survival across all the data sets 19. In an immunohistochemical analysis of 347 non-small cell lung cancer cases, Kvarnbrink et al20 found out that high expression of Lrig1 was an independent prognostic factor that correlated with good survival, particularly among patients with lung adenocarcinoma. However, there are no reports to demonstrate that address the specific function of Lrig1 in the HCC patients.…”

Section: Discussionmentioning

confidence: 99%

Lrig1 is a positive prognostic marker in hepatocellular carcinoma

Yang¹,

Dai²,

Tan³

et al. 2016

OTT

View full text Add to dashboard Cite

BackgroundThe prevalence of hepatocellular carcinoma (HCC) is increasing worldwide. As a consequence, there is an urgent need for identifying molecular markers of HCC development and progression. Recently, several studies have suggested that the Lrig1 may have prognostic implications in various cancer types, but its clinical value in HCC is not well evaluated.Materials and methodsIn this study, the expression level of Lrig1 was examined in 133 HCC tissues and adjacent normal tissues by immunohistochemistry. Furthermore, potential associations between Lrig1 expression and the carcinoma clinical parameters were investigated, including recurrence and survival rate. We silenced the Lrig1 in the normal liver cell line (LO2) and liver cancer cell line (Hep-G2) in vitro by the small interference RNA and detected its influence on proliferation, migration, and invasion.ResultsThe expression of Lrig1 was significantly downregulated in liver cancer tissues and cell lines, and its expression levels were related to tumor size, tumor–node–metastasis staging and tumor recurrence. Furthermore, analysis of 6-year survival of 133 HCC patients showed that those with stronger Lrig1 expression had significantly longer overall survival time than those with weaker Lrig1 expression. In addition, decreased expression of Lrig1 in vitro promoted the growth, migration, or invasion of normal liver cells and cancer cells.ConclusionOur findings demonstrate that Lrig1 could serve as a potential marker in the prognosis of patients with HCC. We also revealed that Lrig1 might be involved in the metastatic progression of liver cancer. However, its clinical value should be further investigated in the future.

show abstract

“… 18 , 34 , 35 The study reported by Kvarnbrink et al analyzed both protein and mRNA levels of LRIG1 expression in 2 different cohorts. 35 A 0 to 3 scoring system was used for analyzing the IHC staining intensities and LRIG1 mRNA levels were stratified as low, intermediate, and high groups. The study reported by Muller et al analyzed the immunoreactivity of LRIG1-3 in 86 cervical adenocarcinoma cases.…”

Section: Discussionmentioning

confidence: 99%

Expression of LRIG1 is Associated With Good Prognosis for Human Non-small Cell Lung Cancer

Zhao

et al. 2015

Medicine

View full text Add to dashboard Cite

Somatic mutations, which are associated with a certain rate of response to targeted therapies, are ubiquitously found in human non-small cell lung cancer (NSCLC). However, it is largely unknown which group of patients may benefit from the respective treatments targeting different somatic mutations. Therefore, more effective prognostic and predictive markers are desperately needed for the treatment of NSCLC harboring different somatic mutations. The leucine-rich repeats and immunoglobulin-like domains (LRIG)-1 is a tumor suppressor gene that belongs to the LRIG family. LRIG1 expression has prognostic significance in various human cancers.In this study, we first used the quantitative polymerase chain reaction (qPCR) and immunohistochemical analysis of 36 and 182 NSCLC patient tissues to analyze the LRIG1 expression respectively. To investigate the prognostic value of LRIG1 in NSCLC, we examined the correlation between clinical features and overall survival (OS) with Cox proportional hazard regression. We also compared the sensitivity and specificity of LRIG1 in NSCLC prognosis by logistic regression to further evaluate the prognostic efficiency of LRIG1 in NSCLC.We found that the LRIG1 expression was associated with pathological type, differentiation status, and stage of NSCLC. The result showed that LRIG1 was an independent prognostic factor for OS of NSCLC patients. LRIG1 in combination with other clinicopathological risk factors was a stronger prognostic model than clinicopathological risk factors alone.Thus, the LRIG1 expression potentially offered a significant clinical value in directing personal treatment for NSCLC patients.

show abstract

LRIG1 is a prognostic biomarker in non-small cell lung cancer

Abstract: These findings demonstrate that LRIG1 is an independent prognostic factor in patients with NSCLC that could be important in future decision-making algorithms for adjuvant lung cancer treatment.

Cited by 27 publications

References 24 publications

Expression of LRIG proteins as possible prognostic factors in primary vaginal carcinoma

Expression of LRIG proteins as possible prognostic factors in primary vaginal carcinoma

Lrig1 is a positive prognostic marker in hepatocellular carcinoma

Expression of LRIG1 is Associated With Good Prognosis for Human Non-small Cell Lung Cancer

Contact Info

Product

Resources

About